Global Companion Animal Health Market - Growth, Trends and Forecasts (2017 - 2022)

The global market for companion animal healthcare is valued at $9.16 billion in 2013. Expected to grow at a CAGR of 7.86%, the market is set to reach $13.37 billion by 2020.

The companion animal health market is segmented based on type of products i. e Vaccines, Paraciticides, Anti-infectives, Medicinal feed additives, and other pharmaceuticals, based on diagnostics i.e Enzyme Linked Immuno sorbent assay(ELISA), Rapid Immuno Migration( RIM), based on genetics,based on geography market is divided into North America, Asia-Pacific, Europe and Rest of World. Europe accounts for the largest share of the animal vaccines market, followed by North America. The developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors in the market.

Pfizer (U.S.), Merck (U.S.), Sanofi-Aventis (France), Bayer HealthCare (Germany), Virbac (France), Novartis (Switzerland), Boehringer Ingelheim (Germany), Heska Corporation (U.S.), Bioniche Animal Health Canada, Inc. (Canada), and Ceva (France) are the key players in the global companion animal health market

What makes our report unique?

1) In depth analysis of current market trends and future forecasts of the market based on different products available for both companion animals and farm animals

2) We provide longest possible market segmentation of the market based on products available, diagnostics, genetics , and geography. We give you the competitive landscape for the market which provides information about major players in the market, Market Share and recent developments.

3) High level analysis on products i.e Vaccines, anti-infectants, MFA, Paraciticides andintroduced novel vaccines such as DNA and recombinant vaccines.


1.1 Market Definition

1.2 Market Recent Trends

2. Market Analysis

2.1 Market Animal Health Products

2.2 Animal medicines vs human Medicines

3. Market Dynamics

3.1 Market Drivers

3.1.1 Increase in pet ownership

3.1.2 Improved Nutrition

3.1.3 Intensifying consumer focus on food safety

3.1.4 Greater Livestock production

3.1.5 Increasing Zoonotic and Foodborne Diseases

3.2 Market Constraints

3.2.1 Scarcity of arable land and water

3.2.2 Increased competition for cultivated land

3.2.3 Cost effective production

3.3 Porter's Five Force Analysis

3.3.1 Threat of New Entrant

3.3.2 Internal Rivalry

3.3.3 Buyer bargaining power

3.3.4 Supplier bargaining power

3.3.5 Threat of substitutes

4.Market Segmentation

4.1 Global Companion Animal Market Segmentation- By products

4.1.1 Paraciticides

4.1.2 Anti-Infectives

4.1.3 Medicinal Feed Additives

4.1.4 Other Pharmaceuticals

4.1.5 Vaccines

4.2 .Companion Animals

4.2.1 Dogs

4.2.2 Cats

4.2.3 Horses

5. Global Companion Animal Diagnostics Market

5.1 Enzyme Linked Immuno Sorbent Assay( ELISA)

5. 2 Rapid Immuno Migration( RIM)

5. 3 Agar gel Immuno Diffusion( AGID)

6. Global Companion Animal Genetics Market

6.1 HD 50K for Angus

6.2 CLARIFIDE for Dairy

6.3 Sheep 50K

6.4 CLARIFIDE for Nelore

6.5 Others

7. Global Companion Market Segmentation, By Geography

7.1 North America

7.1.1 US

7.1.2 Mexico

7.1.3 Canada

7.2 Europe

7.2.1 France

7. 2.2 Italy

7.2.3 Germany

7.2.4 Spain

7.2.5 UK

7.3 Asia-Pacific

7.3.1 India

7.3.2 China

7.3.3 Japan

7.3.4 Rest of Asia-Pacific

8. Competitive landscape

8.1 Major players in the market

8.2 mergers and acquisitions

8.3 New product launches

8.4 Agreement, Collaborations and Partnerships

8.5 Recommendations for new players in the market

8.6 Recommendations for existing players in the market

8.7 Market Share Analysis

9. Company Profiles

9.1 Zoetis animal healthcare

9.1.1 Financial Overview

9.1.2 Business overview

9.1.3 Business strategies

9.2 Merck

9.2.1 Financial Overview

9.2.2Business overview

9.2.3 Business strategies

9.3 Merial (Animal Health Division Of Sanofi)

9.3.1 Financial Overview

9.3.2 Business overview

9.3.3 Business strategies

9.4 Elanco

9.4.1 Financial Overview

9.4.2 Business overview

9.4.3 Business strategies

9.5 Bayer healthcare

9.5.1 Financial Overview

9.5.2 Business overview

9.5.3 Business strategies

9.6 Novartis Animal Health, Inc.

9.6.1 Financial Overview

9.6.2 Business overview

9.6.3. Business strategies

9.7 Virbac

9.7.1 Financial Overview

9.7.2 Business overview

9.7.3 Business strategies

9.8 Boehringer Ingelheim

9.8.1 Financial Overview

9.8.2 Business overview

9.8.3 Business strategies

10. Appendix





Content are not available

Choose License Type